NFKB1 and neoplasm: Currently, the present TAM-targeted therapeutics consist of (i) suppressing macrophage recruitment (such as CCL2 inhibitors and CSF-1R inhibitors); (ii) inhibiting TAM survival (e.g., bisphosphonates); (iii) increasing the tumouricidal activity of M1 macrophages (for example, agonists of the NF-κB signaling pathway such as TLR-7 agonist and other agents such as IL-12); and (iv) limiting the tumor-promoting activity of M2 macrophages (inhibitor of STAT3).